GAGomes as early detection biomarkers: multi-cancer

Recent evidence suggests that metabolic reprogramming of GAGomes is an ubiquitous process in cancers. In a clinical study with over 1’500 samples across 14 cancer types, a multi-cancer GAGome signature was detected in the plasma and urine that was significantly elevated already in stage I in every cancer type tested.

Preclinical evidence in mice supports a causal link between cancer initiation and changes in the GAGome providing mechanistic insight on its value for early detection.

‍
Elypta is currently validating the use of GAGomes for multicancer early detection in LEVANTIS-0087A.